Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...

More than 10 million older adults in the U.S. have mild or greater valvular heart disease and the prevalence is expected to grow over the next several decades, according to data from the PREVUE-VALVE ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort from the American Heart Association designed to boost clinical trial ...

Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

in patients with severe calcific aortic stenosis and to support a future PMA submission. “We are extremely pleased to receive FDA approval for the PARADIGM Trial, which allows us to commence patient ...

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

A troubling rise in severe diverticulitis cases among Americans under 50 highlights a significant public health concern.

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of ...

Anteris Technologies (Nasdaq:AVR) today announced one-year clinical outcomes for its DurAVR transcatheter heart valve (THV).